Conflicts of interest
TG
EMD
MG is a contractor for F. Hoffmann-La Roche Ltd. JSG over the past year has received grant/contract research support from the National MS Society, Biogen, and Octave Biosciences. She serves on a steering committee for a trial supported by Novartis. She has received honoraria for a non-promotional, educational activity for Sanofi Genzyme. She has received speaker fees from Alexion and BMS and served on an advisory board for Genentech. SPH is a contractor for F. Hoffmann-La Roche Ltd. FD was an employee of and is a shareholder in F. Hoffmann-La Roche Ltd; he is currently employed by Novartis Institutes for Biomedical Research. LM has nothing to disclose. LG is an employee of F. Hoffmann-La Roche Ltd. LC is an employee of and shareholder in F. Hoffmann-La Roche Ltd. FL is an employee of F. Hoffmann-La Roche Ltd. CB is a contractor for F. Hoffmann-La Roche Ltd. XM has received speaking honoraria and travel expenses for participation in scientific meetings; has been a steering committee member of clinical trials; or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, Genzyme, Immunic, Medday, Merck, Mylan, Nervgen, Novartis, Roche, Sanofi-Genzyme, Teva, TG Therapeutics, Excemed, MSIF, and NMSS. SLH serves on the scientific advisory boards for Alector, Annexon, and Accure; is on the Board of Directors for Neurona Therapeutics; and has received travel reimbursement and writing assistance from F. Hoffmann-La Roche Ltd and Novartis for CD20-related meetings and presentations. ML is a consultant for F. Hoffmann-La Roche Ltd via Inovigate.